source
- Swiss biotech Windward Bio raises $175 million in IPO to fund lung-drug development and test Tezspire competitorWindward Bio, a Swiss immune‑drug developer, completed a $175 million initial public offering, selling about 10.3 million shares at $17 each. The company began trading on the exchange under the tic…
- STAT+: Across the U.S., homegrown experiments aim to save kids from their phonesAs researchers struggle to understand phone addiction, young people are finding ways to reclaim their attention and push back against Big Tech.STAT · 51m ago↗ source